The Clot Wars – New Rivals to Warfarin as Blood Clot Preventer
Posted Sep 07 2010 2:33pm
For investors who have been asking themselves whether medium-size pharmaceutical companies can survive in an industry that has had recent mega-mergers, the answer seems to be yes. At least for Bristol-Myers Squibb.
The company’s experimental anticoagulant drug apixaban worked better than aspirin in preventing stroke and systemic blood clots for patients who have an irregular heart rhythm disorder called atrial fibrillation, according to new study data presented on Tuesday at a cardiology conference in Stockholm.
Investment bank analysts have estimated that a new generation of stroke prevention drugs like apixaban, if approved by the Food and Drug Administration, could generate $10 billion or more in annual global sales.